



Beyond molecular tumor heterogeneity: protein synthesis takes
control
Santiago Ramon y Cajal 1,2,3 ● Josep Castellvi1,2,3 ● Stefan Hümmer1,3 ● Vicente Peg 1,2,3 ● Jerry Pelletier4 ●
Nahum Sonenberg4
Received: 2 October 2017 / Revised: 15 December 2017 / Accepted: 2 January 2018 / Published online: 21 February 2018
© The Author(s) 2018. This article is published with open access
Abstract
One of the daunting challenges facing modern medicine lies in the understanding and treatment of tumor heterogeneity.
Most tumors show intra-tumor heterogeneity at both genomic and proteomic levels, with marked impacts on the responses of
therapeutic targets. Therapeutic target-related gene expression pathways are affected by hypoxia and cellular stress.
However, the finding that targets such as eukaryotic initiation factor (eIF) 4E (and its phosphorylated form, p-eIF4E) are
generally homogenously expressed throughout tumors, regardless of the presence of hypoxia or other cellular stress
conditions, opens the exciting possibility that malignancies could be treated with therapies that combine targeting of eIF4E
phosphorylation with immune checkpoint inhibitors or chemotherapy.
Introduction
Owing to increased incidence, cancer is now the second
most common cause of death in developed countries and the
leading cause of death in individuals above 40 years of age
[1]. The number of cancer-related deaths is expected to
grow due to increases in life expectancy and lifestyle risk
factors. Although current treatments have improved patient
survival, the results remain dismal for advanced disease. For
example, the 5-year survival rate is only 2% for stage IV
lung cancer and 25% for breast cancer patients with meta-
static disease [2]. In contrast, the 5-year survival of patients
with in situ breast cancer exceeds 90%. Indeed, despite the
development of a new arsenal of molecular targeted
therapies over the last decade, patient survival with
advanced cancer has improved by only 15% [1, 2]. One of
the main reasons for these disappointing outcomes is the
pervasive heterogeneous expression of drug targets within
human tumors.
Cancer can be viewed as a group of heterogeneous dis-
eases that arise from a small number of initiation events, but
phenotypically diverge during progression due to environ-
mental context (site of origin), the acquisition of different
mutations required for survival, and individual patient
responses to the tumor. Heterogeneity is observed at the
genetic, proteomic, morphological, and environmental
levels.
Tumor cell adaptability often leads to the use of redun-
dant signaling pathways in response to stress, such as
hypoxia and reduced nutrient availability. Within a tumor
bed, variations in the “strength” of these stressor events and
the corresponding responses can result in a significant
degree of heterogeneity in gene expression, with some cells
needing to respond more acutely than others. In this review,
we underscore the nature of eukaryotic initiation factor (eIF)
4E in malignant tumors as a critical effector of cell signaling
networks. We summarize the findings that the phosphory-
lated forms of eIF4E and 4E-BP1, termed p-eIF4E and p-
4E-BP1, show a predominantly homogenous expression
pattern within tumor beds, a feature that we predict to be
actionable and to hold significant consequences for cancer
therapy.
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Fig. 1 a Diagram representing clonal selection according to a Dar-
winian model. The best-adapted clones due to genetic or epigenetic
advantages or with better interplay with neighboring cells will survive
and proliferate, becoming the dominant clone until a new “selective
barrier” appears. The tumor clonal composition varies over time,
although, microscopically, these changes can be subtle or not evident.
b Clonal cooperation and feature complementation. Puzzle diagram
illustrating the contribution of individual cell clones with different
tumor-promoting features to the formation of a tumor. The main fea-
ture of each clonal population within a tumor is shown as legend on
the left side. The cooperation between different clones results in dif-
ferent functional consequences for the tumor, which are summarized in
the middle of the figure
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Clonal evolution during cancer progression
A complex molecular scenario is responsible for tumor
initiation and tumor progression. It is well established that,
in a single tumor, cell clones with novel genetic alterations
arise constantly and are selected according to a Darwinian
model [3]. Concomitantly, there is also cross talk between
the tumor clones and the microenvironment that affect the
ability of tumors to survive and proliferate. In fact, the
cooperation between clones and the microenvironment is
similar to that of a tumor consortium (Fig. 1) [4]. The new
genetic alterations are driven by genetic instability, one of
the hallmarks of tumor cells [5]. Only a small proportion of
the total mutational burden is related to the process of clonal
evolution because most are passenger mutations with no
biological relevance [5]. In addition, treatments can alter
clonal heterogeneity by selecting for more resistant cells or
perturbing the microenvironmental conditions [6].
Epigenetic differences between clones are critical to
tumor heterogeneity. Many of them are associated with an
aberrant DNA methylation pattern, histone modification, or
microRNA transcriptome and can be related to micro-
environment factors [7]. Thus, both genome and epigenome
diversity enables malignant tumor clones to acquire all of
the capabilities to survive, proliferate, and invade neigh-
boring or distant tissues [8–12].
The microenvironment appears to be important for the
selection of the best-adapted clones. Contributors include
neighboring cells (e.g., fibroblasts and immune cells),
growth factors, cytokines, hypoxia, and nutrient availability
[13–16]. Hence, variations among tumor microenviron-
ments may be responsible for some of the phenotypic het-
erogeneity observed within tumor beds. Consequently, the
microenvironment may also have an impact on the selection
of specific clones with different driver/maintenance muta-
tions in topologically segregated areas of a tumor, which
together affect the evolutionary trajectory of the disease
(Fig. 1a).
Clonal accumulation and response to
anticancer agents
The proteomic complexity of tumors must be fully under-
stood to develop more effective therapeutic strategies.
Pathologists have long recognized that not all cells within a
given tumor express the same amounts of a large number of
proteins. For example, the expression of cyclin D1 in
mantle cell lymphoma is not homogeneous even when all of
the tumor cells carry the signature CCND1-IGH transloca-
tion [17]. Likewise, hormone receptor expression in breast
carcinoma is often non-homogenous and irregular within a
given tumor bed. The protein intra-tumor heterogeneity is
mirrored in some cases at the transcriptional level and has
been well documented by single-cell RNA-sequencing in
glioblastomas [18]. Moreover, the latter study noted varia-
tions in the expression level and differences in cell signaling
receptor and cell proliferation markers. In addition, differ-
ences in post-translational modifications of a given protein
among cancer cells in a single tumor have been documented
[19, 20].
The consequences of this pervasive lack of uniformity
between cancer cells are grim for patients. It is a major
cause of treatment failure in many patients, particularly in
those treated with molecular targeted therapies [21]. If a
fraction of cancer cells in the tumor do not express a par-
ticular drug target or have evolved to no longer be depen-
dent on its presence/activity, then it stands to reason that
these cells will fail to be eliminated by targeted therapies. A
case in point is HER2+ (human epidermal growth factor
receptor 2) breast cancers, with the classification requiring
that only 30% of the cells have to stain positive for HER2
by immunocytochemistry. Clearly, treatment with anti-
HER2 therapies cannot be expected to be curative in such a
context. Similarly, therapies based on rapamycin fail
because of the uneven and heterogeneous expression of p-
mTOR [22–24].
It is noteworthy that this same target expression issue
may also affect the outcomes of immunotherapeutic
approaches. Most patients with B cell malignancies who are
treated with chimeric antigen receptor (CAR) T cells tar-
geting CD19 will initially respond to therapy, but about
30% will relapse. The relapse appears to be because the
tumor cells express a novel CD19 isoform arising from
alternative splicing and lacking the exon encoding the
antigenic epitope [25]. One way around this problem is to
combine multiple therapies after tumor mutational profiling
[26–28], but appropriate clinical trials are required to ensure
that the resulting combination is not antagonistic.
Identifying the status of the protein
synthesis machinery and the key regulators
of translational control
Choosing targets whose expression levels do not vary sig-
nificantly among cancer cells and whose expression cannot
be extinguished (i.e., essential targets) is a logical step to
deal with the issue of heterogeneity. Such potential targets
include components of the translation apparatus, an essen-
tial biochemical process, with recent experience showing
that an optimal therapeutic index can be obtained when this
process is targeted in cancer cells [20, 21, 26, 27]
Two of the most important regulatory signal transduction
pathways that modulate cellular translation rates are the
RAS-RAF-ERK1/2 and PI3K-AKT/mTOR [29–31]
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pathways. These pathways are crucial to the development of
targeted therapies because many of their components are
changed in the vast majority of human cancers (e.g., HER2,
PI3K, RAS, and RAF) [32]. What is generally under-
appreciated is that components of the translation regulatory
machinery (namely, 4E-BP1, eIF4E, and eIF4A) involved
in the ribosome recruitment phase of translation initiation
fall under the control of these pathways (Fig. 2) [33, 34].
The eIF4F complex, consisting of eIF4E (the cap-binding
protein), eIF4A (a DEAD-box RNA helicase), and eIF4G (a
large scaffolding protein), regulates ribosome recruitment to
mRNA templates [35]. This step in translation initiation is
thought to be rate-limiting for protein synthesis. The
assembly of eIF4F is regulated by mTOR via phosphor-
ylation of 4E-BPs (of which there are three, with 4E-BP1
being the best studied), as well as of PDCD4 [36–39].
Fig. 2 Schematic representing
the signaling cascade regulating
translation initiation. The key
event is the dissociation of
eIF4E from 4E-BP1 by different
signaling pathways under
normal growth conditions and in
response to stress
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Binding of 4E-BP1 to eIF4E prevents eIF4F complex for-
mation [40]. mTOR activation (as occurs in a broad range of
human cancers) causes direct phosphorylation of 4E-BP1
and its dissociation from eIF4E to consequently stimulate
eIF4F formation [41–43]. eIF4F discriminates between
different mRNAs and therefore an increase in eIF4F levels
or activity causes a selective change in the translatome.
Although the features responsible for mRNA discrimination
by eIF4F are not completely understood, cap accessibility
and 5′ leader secondary structure are important contributors
[44–46]. PDCD4 forms an inhibitory complex with eIF4A
and phosphorylation of the former by S6K1/2 leads to its
degradation and allows eIF4A to enter the eIF4F complex
[38, 39]. In addition, eIF4E can be directly phosphorylated
upon activation of the RAS-RAF-ERK1/2-MNK pathway
or through p38 and this is also associated with a selective
increase in translation, the mechanistic basis of which
remains to be elucidated [47–51].
4E-BP1 harbors seven phosphorylation sites and,
although mTOR is the most prominent kinase targeting
these sites, other kinases, such as CDK1, ATM, PI3K-AKT,
ERK1/2, and PIM1, also phosphorylate 4E-BP1 [52, 53].
Therefore, 4E-BP1 phosphorylation can be the consequence
of many different oncogenic events that modulate disparate
signaling pathways or that occur via several mechanisms,
including amplification or mutation of growth factor
receptors or mutations in critical oncogenes (e.g., PTEN,
ATM, p53, PI3K, or RAS). Our current understanding of
perturbed translation initiation in cancer cells is that the
eIF4E/4E-BP1 ratio is critical to sustain the oncogenic
features of a transformed cell. Ultimately, this essential
node may act as a “bottleneck” or “funnel factor” to sustain
transformation, regardless of the upstream oncogenic
alterations [54] (Fig. 2).
Expression of signaling factors in human
tumors
In the past decade, by analyzing more than 2500 human
tumor samples [55–60], we have assessed the expression of
membrane receptors such as EGFR and HER2, components
of the RAS/RAF/ERK and PI3K/AKT/mTOR pathways,
and their effectors such as p70S6K, 4E-BP1, eIF4E, and p-
Fig. 3 a–h Invasive ductal carcinoma a–g (×200), h (×400). Immu-
nohistochemistry for a p-ERK1/2, b p-S6, c p-4E-BP1, d p-eIF4E, e p-
AKT, and f p-mTOR. g, h GLUT-1 Immunohistochemistry was per-
formed as described previously [58] using the following primary
antibodies: p-eIF4E (Abcam, Ab76256), p-4E-BP1 (T37/46) (Cell
Signaling, #2855), pS6 (S235/236) (Cell Signaling, #2211), p-ERK1/2
(T202/Y204) (Cell Signaling, #9101), p-mTOR (Ser2448) (Cell Sig-
naling #2971); p-Akt (Ser473) (Cell Signaling #3787), GLUT-1
(Abcam, Ab652)
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eIF4E. We have found that increased amounts of total or p-
eIF4E, as well as p-4E-BP1, are associated with malignant
progression and adverse prognosis in several tumors,
including breast, lung, ovary, endometrium, glioma, and
prostate cancers, regardless of the upstream oncogenic
alterations (Figs. 3 and 4) [22]. Other groups have con-
firmed the prognostic importance of these factors in addi-
tional tumor types (Table 1), including colon cancer [61,
62], nasopharyngeal carcinoma [63], hepatocellular carci-
noma [64], astrocytomas [65], lung cancer [66, 67], and
melanoma [68]. Importantly, eIF4E is a central regulator of
metastatic progression [69–71] (Fig. 4).
Thus, the eIF4E/4E-BP1 node appears to act as a
restriction point for essential oncogenic features such as
self-sufficiency in growth signals and should serve as a
highly relevant molecular marker of malignant potential.
Interestingly, the expression of eIF4E and 4E-BP1 and their
phosphorylated forms is apparent even in the presence of
upstream receptor or kinase overexpression (e.g., AKT,
mTOR, or ERK), suggesting that other mechanisms are
involved in their regulation. The expression of p-AKT or p-
mTOR is highly heterogeneous within a tumor, whereas the
expression of 4E-BP1 and eIF4E is more homogeneous
(Fig. 3) [22]. This may be due to the activation status of the
global growth signaling and proliferative network in being
able to maintain a certain flux threshold rather than the
necessity of maintaining activity of a specific player. Even
in tumors showing constitutive expression of EGFR and
HER2, the global gene expression program is not necessa-
rily permanently fixed or homogeneous in all cells. Inter-
estingly, the geographic context of the tumor cell may
impinge on the expression levels of these pathways [72].
For example, some markers are more highly expressed at
the invasive front or around necrotic areas, suggesting that
ischemia or other microenvironmental factors impinge on
their expression or activity (Figs. 3 and 5).
Perspectives in tumor heterogeneity beyond
genetics
The microenvironment has a key role in selecting the best-
adapted cancer clone and can alter communication networks
between different cancer cell types. The aberrant informa-
tion flow in cancer cells leads to alterations in gene reg-
ulatory networks that support the cancer hallmarks [73] and
can be influenced by features such as cytokines, exosomes,
hypoxia, starvation, and oxidative stress (Fig. 5). In this
Fig. 4 a–d Low-grade lung adenocarcinoma (×400). e–h High-grade lung squamous carcinoma (×200). Immunohistochemistry for p-ERK1/2 (a,
e), p-S6 (b, f), p-4E-BP1 (c, g), and p-eIF4E (d, h). Immunohistochemistry was performed as described previously [58]
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respect, modulating the translational program is thought to
ensure the expression of factors, which confer resistance to
cellular stress [74] (Fig. 3). In most malignant cells, the cap-
dependent pathway is highly upregulated and interference
with this translational program has been shown to be an
attractive venue for novel therapeutics that ultimately pre-
vent the adaptation of tumor cells to stress conditions. The
main therapeutic approaches targeting the 5′ cap-dependent
translational machinery (summarized in ref. [33]) are
directed against, the expression of eIF4E [75, 76], the
interaction between eIF4E-4G [77, 78], the binding of
eIF4F complex to the 5′-cap structure [79, 80], the eIF4A
helicase activity [81–84], the phosphorylation status of
eIF2α [85, 86], and the kinase activity of MNK1/2 [87–91].
Among the different strategies that prevent 5′ cap-
dependent translation under stress conditions, it is
believed that inhibition of MNKs may be a powerful way to
increase the efficacy of other anti-tumor agents, as phos-
phorylation of its downstream target eIF4E has been shown
to confer resistance to cellular stress, genomic damage, lack
of nutrients, and oxidative stress (Fig. 5) [92, 93]. In fact,
several companies are developing inhibitors of MNK1/2
activity [94], and at least one of them (eFT508) is already
being studied in a clinical phase II trial. Impressive data
Table 1 Prognostic significance of total and phosphorylated eIF4E and 4E‐BP1 in malignant tumors
Primary tumor Clinical significance References
Bladder p-4E-BP1 correlates with prognosis in patients with muscle-invasive bladder cancer Nishikawa et al. [96]
Breast Increased expression of eIF4E in invasive ductal carcinoma correlate with presence of lymph node
metastasis
Hu et al. [97]
4E-BP1 is an independent prognostic factor and is associated a poor response to endocrine therapy Karlsson et al. [98]
eIF4E predicts survival after anthracycline chemotherapy in breast cancer patients Heikkinen et al. [99]
eIF4E expression is related to breast cancer survival and it is modulated by 4E-BP1 Coleman et al. [100]
p-4E-BP1 correlates with grade and prognosis in breast cancer Rojo et al. [60]
High eIF4E is an independent predictor of recurrence in breast cancer. Li et al. [101]
Cervix Overexpression of p-4E-BP1 predicts recurrence and reduced survival in cervical carcinoma Benavente et al. [55]
CNS p-eIF4E is an independent prognostic factor in astrocytoma Martínez-Saez et al. [58]
p-4E-BP1 expression increase with tumor grade and predicts survival in astrocytomas Korkolopoulou et al. [102]
Colon High 4E-BP1 expression is associated with poor prognosis Chen et al. [103]
High expression of eIF4E is associated with advanced stage and poor prognosis Chao et al. [61]
Endometrium p-4E-BP1 is associated with high-grade endometrial carcinomas and worse prognosis Castellvi et al. [57]
p-4E-BP1 is associated with stage and high-grade tumors Darb-Esfahani et al. [104]
Esophagus p-4E-BP1 expression after chemoradiotherapy is a predictor for recurrence and worse survival in
esophageal carcinoma
Chao et al. [105]
p-4E-BP1 is associated with poor prognosis in early stage esophageal carcinoma Yeh et al. [106]
Head and neck eIF4E expression is associated with tumor stage, lymph node metastasis and grade of
differentiation
Han et al. [107]
p-eIF4E and p-MNK1 are independent prognostic factors in nasopharyngeal carcinoma Zheng et al. [63]
Kidney p-4E-BP1 is associated with poor prognosis in Xp11.2 translocated renal cell carcinoma Qu et al. [108]
p-4E-BP1 and eIF4E are independent prognostic factors in clear cell renal cell carcinoma Campbell et al. [109]
p-4E-BP1 is a prognostic predictor in patients with metastatic renal cell carcinoma Nishikawa et al. [110]
Liver eIF4E overexpression is an independent indicator for overall survival in hepatocarcinoma Jiang et al. [64]
p-4E-BP1 is overexpressed in cholangiocarcinomas with poor differentiation and lymph node
metastasis, and is an independent prognostic factor
Fang et al. [111]
Lung p-4E-BP1 expression is associated with poor prognosis in small-cell lung cancer Roh et al. [66]
p-4E-BP1 Thr70 predicts poor prognosis in non-small-cell lung cancer Lee et al. [112]
p-4E-BP1 and eIF4E are prognostic factors in stage I lung adenocarcinoma Seki et al. [113]
High eIF4E expression correlates with poor prognosis in lung adenocarcinomas Wang et al. [114]
Melanoma eIF4E is associated with melanoma thickness and overall survival Khosravi et al. [68]
p-4E-BP1 is associated with poor survival in melanoma O’Reilly et al. [115]
Ovary p-4E-BP1 is a prognostic factor in ovarian cancer Castellvi et al. [56]
Stomach p-eIF4E is overexpressed in tumors with lymph node metastasis Tapia et al. [116]
p-4E-BP1 is a prognostic factor in gastric cancer patients and correlates with advanced stage Jiao et al. [117]
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have been obtained from preclinical models of diffuse large
B cell lymphoma, non-small-cell lung carcinoma, and breast
adenocarcinoma. Moreover, the inhibitor eFT508 enhances
the efficiency of anti-PDL1 checkpoint blockade inhibitors
[95]. Similarly, blockage of 4E-BP1 phosphorylation by
inhibition of upstream signaling activity (e.g., mTOR) will
decrease eIF4F levels and dampen cap-dependent transla-
tion and tumor cell growth [40].
In summary, tumor heterogeneity must first and foremost
be considered by a treating oncologist after a cancer diag-
nosis and be a key factor in the determination of a ther-
apeutic target following mutation profiling. We know that
intra-tumor heterogeneity is dynamic, occurs at multiple
levels, and follows a Darwinian model. Still unresolved is
the number of biopsies or sections required from the pri-
mary specimen to determine the extent of molecular target
Fig. 5 a Schematic drawing of a
tumor and the tumor
microenvironment. Left: Cells
within a tumor exposed to
different microenvironmental
cues. Nutrient and O2 supply
decreases from the periphery to
the center of the tumor while
stress conditions are elevated.
Right: Genetic alterations of
cells within a tumor are depicted
by different colors. Importantly,
genetic alterations are not
strictly limited to the different
environmental conditions. b
Scheme depicting the staining
pattern of different proteins
involved in the signaling
cascade regulating translation
initiation (top), as shown in Figs.
3 and 4. GLUT1 serves as a
marker for hypoxic conditions
within the tumor (bottom)
Beyond molecular tumor heterogeneity... 2497
heterogeneity. Moreover, relapses and metastases need to be
analyzed to understand how they differ from the primary
tumor. Given the complexities of these issues, collaboration
among oncologists, radiologists, pathologists, bioinforma-
ticians, and molecular biologists is required to offer the best
care to patients. Finally, it is clearly of paramount impor-
tance to explore intervention strategies that target critical
factors involved in regulating translation, such as eIF4E.
With the rigorous evaluation of combinations of small-
molecule eIF4E or MNK1/2 inhibitors with other ther-
apeutics (e.g., cytotoxics, targeted therapies, immunother-
apy), the issue of proteomic heterogeneity can start to be
therapeutically addressed.
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